Metastatic uveal melanoma: biology and emerging treatments
about
Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interactionGenome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma.The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo.Systematic genomic and translational efficiency studies of uveal melanoma.Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization.Current and emerging treatment options for uveal melanoma.Translational models of ocular disease.Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration.Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience.The pharmacological NF-κB inhibitor BAY11-7082 induces cell apoptosis and inhibits the migration of human uveal melanoma cellsMolecular pathology of uveal melanomaThe Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver Malignancies.Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing.Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activationClinicopathological characteristics of vascular endothelial growth factor expression in uveal melanoma: A meta-analysis.Posterior reversible leukoencephalopathy syndrome secondary to hepatic transarterial chemoembolization with doxorubicin drug eluting beadsEvolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.HIC1 modulates uveal melanoma progression by activating lncRNA-numb.Rare tumors: an eye on the future.Tumor-targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells.Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.Ocular melanoma metastasizing to intra-abdominal lymph nodesSolitary secondary malignant melanoma of clavicle two years after enuclation for ocular melanoma.Clinicopathological Characteristics and Prognosis for Survival after Enucleation of Uveal Melanoma in Chinese Patients: Long-term Follow-up.Expression of the Metastasis Suppressor KAI1 in Uveal Melanoma.New trends in the multidisciplinary treatment of liver tumors.Recent advances in uveal melanoma treatment.Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma.Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma.[Ocular melanomas : An update].Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications.Cancer and the arts: metastasis-as perceived through the ages.
P2860
Q28393257-0904C0A9-06AC-45FD-811F-22DE5A10B448Q33659480-D51D85BC-E20F-4E24-AA98-E42FBCDCE8C5Q33703068-DD869CB9-E2A1-4DBA-9772-390B8E661038Q33778295-DE286358-45F3-435C-B606-6A58418177E6Q34369283-11099FE3-4786-43C7-8207-67DB15590C54Q34655878-74F60C44-D0A5-4062-B048-50CB558BE2B6Q34764453-C04F09BA-E46F-443D-9437-D1D5E58D44E3Q35097186-840EE742-365C-4304-B447-14CCBE60192CQ35854809-CCA8D4A8-1A8A-4033-9F11-23B4D8BE3939Q36538277-F3CD488D-17AC-425E-BB45-8AD7FB3B397FQ36615059-A9D20186-9828-4A7A-B2DB-2E3BE1FD666FQ36771989-15AAE641-E5C3-43C4-B910-12665767AEFAQ36863359-34D1FFA4-C919-4858-9AB8-6CB51785CC59Q36874742-71661701-A404-46A1-9C47-AD4273EE149BQ37061324-C1789BF1-C946-429A-847C-13541750AE1DQ37269087-0AB0D132-9BF3-46C2-A8D2-30CA4587D8F4Q37396884-42900218-C596-4A65-AC59-7190EACC661EQ37545095-B96C9E17-B6EE-4B54-9DFE-362BADD51794Q37722192-C1A82A49-CA6D-49E7-B9BC-4D121A0EE956Q37723265-DD8E2787-9BA8-4DEA-BF95-147EB5CD46E5Q38646057-DCF561FB-685A-4535-B1E2-44BCA487077BQ38736921-9376FB05-1D04-4FBF-B07E-2396CA14BA56Q38966454-87D728ED-64EF-4DCB-AE0D-A58C4920BB20Q39100702-03BD442D-9E3F-420C-846B-D6BA453B9276Q40082486-4486B021-A7D9-420D-A059-19EE77D8BD96Q41428376-ECBE8250-E92F-45EC-A6C8-25A9FE0CE0D9Q41813641-D24297D0-BFD4-459F-BF56-6039E5E923ABQ42502565-213141B4-6FF0-44D5-B342-F7F1113497ABQ42560404-154DCC31-8F1D-49BC-B1AC-BFF462DC47DFQ42611507-A8D4B908-940F-49C1-8225-D940049A6B18Q47571643-E48677B4-53D8-4ED9-9137-9E564174ED06Q49698247-53B391AA-D15D-4460-8373-2F37A6E04E09Q50071583-466621A0-5768-4065-AC56-36CC43846137Q50077796-8B68311D-8926-425F-9FE5-223CEE7E158FQ53017847-EDBC3631-9984-4007-BEB8-844B3258EB10Q54974731-23CE0E5B-C55D-4C4B-9595-9735307CD388
P2860
Metastatic uveal melanoma: biology and emerging treatments
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Metastatic uveal melanoma: biology and emerging treatments
@ast
Metastatic uveal melanoma: biology and emerging treatments
@en
Metastatic uveal melanoma: biology and emerging treatments
@nl
type
label
Metastatic uveal melanoma: biology and emerging treatments
@ast
Metastatic uveal melanoma: biology and emerging treatments
@en
Metastatic uveal melanoma: biology and emerging treatments
@nl
prefLabel
Metastatic uveal melanoma: biology and emerging treatments
@ast
Metastatic uveal melanoma: biology and emerging treatments
@en
Metastatic uveal melanoma: biology and emerging treatments
@nl
P2860
P1433
P1476
Metastatic uveal melanoma: biology and emerging treatments
@en
P2093
Scott E. Woodman
P2860
P304
P356
10.1097/PPO.0B013E31824BD256
P407
P577
2012-01-01T00:00:00Z